Olaparib is a medicine used to treat certain types of cancer. It belongs to a group of drugs called PARP inhibitors. These drugs work by blocking a protein called PARP, which helps repair damaged DNA in cells. When PARP is blocked, cancer cells with certain genetic mutations are unable to repair themselves properly, leading to their death.
Olaparib is mainly used to treat two types of cancer: ovarian cancer and breast cancer. Specifically, it's used in patients with ovarian cancer who have mutations in the BRCA genes. These mutations make the cancer cells more vulnerable to the effects of Olaparib. In breast cancer, Olaparib is used in patients with advanced or metastatic disease who have BRCA mutations and have previously been treated with chemotherapy.
One of the advantages of Olaparib is that it can be taken orally, usually in the form of tablets. This makes it more convenient for patients compared to some other cancer treatments that require intravenous infusions or injections.
Like any medication, Olaparib can cause side effects. Some common side effects include nausea, fatigue, vomiting, diarrhea, and loss of appetite. These side effects are usually mild to moderate and can often be managed with supportive care or adjustments to the dosage.
However, Olaparib can also cause more serious side effects in some cases. One potential concern is the risk of developing a condition called myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These are blood disorders that can occur as a rare complication of treatment with Olaparib. Patients should be monitored closely for signs of these conditions, such as persistent fever, unusual bruising or bleeding, or fatigue.
Before starting treatment with Olaparib, patients will undergo genetic testing to determine if they have the specific mutations that make them eligible for this therapy. This testing helps ensure that Olaparib is being used in patients who are most likely to benefit from it.
In addition to its use as a standalone treatment, Olaparib is also being studied in combination with other cancer therapies. Researchers are investigating whether combining Olaparib with chemotherapy, immunotherapy, or other targeted therapies can improve outcomes for patients with certain types of cancer.
Overall, Olaparib represents an important advancement in the treatment of ovarian and breast cancer, particularly for patients with BRCA mutations. While it's not suitable for everyone, it offers hope to many patients by providing a targeted and effective treatment option with manageable side effects. As research continues, the role of Olaparib in cancer treatment may expand, potentially benefitting even more patients in the future.
Have any queries, book a consultation with our Oncology Clinical Specialist
top of page
₹500.00Price
bottom of page